In the EMPOWER-Lung 1 study, cemiplimab, a fully human, hinge-stabilized, immunoglobulin G4, anti-PD-1 mAb, also significantly improved PFS (median 8.2 vs. 5.7 mo, HR = 0.54, 95% CI: 0.43–0.68) and OS (median did not reach vs. 14.2 mo, HR = 0.57, 95% CI: 0.42–0.77), compared with chemotherapy in patients with advanced NSCLC expressing PD-L1 of at least 50% [24]. Here, CD274 is linked to non-small cell lung carcinoma.